KALA BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
KALA BIO, INC. (KALA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 689.52 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-04-15
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was 1.66K shares.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was -3.92M shares, a 1280.68% decline year-over-year.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-06-30 was 303.00K shares, a 229.35% increase year-over-year.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-03-31 was 3.70M shares, a 144.45% increase year-over-year.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 689.52K shares, a 117.42% increase from fiscal 2024.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 317.14K shares, a 52.45% decline from fiscal 2023.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 666.96K shares, a 701.43% increase from fiscal 2022.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 83.22K shares, a 86.06% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 689.52K shares 10-K · filed 2026-04-15 | |||
| 2024-12-31 | 317.14K shares 10-K · filed 2026-04-15 | |||
| 2023-12-31 | 666.96K shares 10-K · filed 2025-03-31 | |||
| 2022-12-31 | 1.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -3.92M shares derived: sum of 2 quarters · filed 2024-03-29 | -3.62M shares derived: sum of 3 quarters · filed 2024-03-29 | 83.22K shares 10-K · filed 2024-03-29 |
| 2022-09-30 | -3.92M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -3.62M shares derived: sum of 2 quarters · filed 2022-11-08 | 81.56K shares 10-Q · filed 2022-11-08 | -1.81M shares derived: sum of 4 quarters · filed 2023-03-03 |
| 2022-06-30 | 303.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 4.00M shares 10-Q · filed 2022-08-11 | 2.11M shares derived: sum of 3 quarters · filed 2023-03-03 | 2.44M shares derived: sum of 4 quarters · filed 2023-03-03 |
| 2022-03-31 | 3.70M shares 10-Q · filed 2022-05-16 | 1.81M shares derived: sum of 2 quarters · filed 2023-03-03 | 2.14M shares derived: sum of 3 quarters · filed 2023-03-03 | 2.23M shares derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-12-31 | -1.89M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | -1.56M shares derived: sum of 2 quarters · filed 2023-03-03 | -1.47M shares derived: sum of 3 quarters · filed 2023-03-03 | 44.73K shares 10-K · filed 2023-03-03 |
| 2021-09-30 | 332.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 424.00K shares derived: sum of 2 quarters · filed 2021-11-15 | 1.94M shares 10-Q · filed 2021-11-15 | |
| 2021-06-30 | 92.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 1.60M shares 10-Q · filed 2021-08-05 | ||
| 2021-03-31 | 1.51M shares 10-Q · filed 2021-05-05 | |||
| 2019-06-30 | 452.22K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | 1.24M shares 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | 791.17K shares 10-Q · filed 2019-05-09 | |||
| 2018-09-30 | 644.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | 747.89K shares derived: sum of 2 quarters · filed 2018-11-08 | 747.89K shares 10-Q · filed 2018-11-08 | |
| 2018-06-30 | 103.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | 103.01K shares 10-Q · filed 2018-08-09 | ||
| 2018-03-31 | 0.00 shares 10-Q · filed 2018-05-10 | |||
| 2017-09-30 | 644.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | 747.89K shares 10-Q · filed 2017-11-07 | ||
| 2017-06-30 | 103.01K shares 10-Q · filed 2017-08-31 | |||
| 2016-09-30 | 15.77K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | 1.52M shares 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | 1.50M shares 10-Q · filed 2017-08-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |